Predictabiosciences
Cambridge, US · Founded 2023 · 21 employees on LinkedIn · 2 known investors
Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.
Founders & leadership
Predictabiosciences was founded in 2023 by Irene Ghobrial, Kenneth Anderson, Gad Getz, Romanos Sklavenitis-Pistofidis, and Keith Flaherty.
IG
Irene GhobrialCo-founder
KA
Kenneth AndersonCo-founder
GG
Gad GetzCo-founder
RS
Romanos Sklavenitis-PistofidisCo-founder
KF
Keith FlahertyCo-founder
BM
Brian McKernanCEO
Investors · 2
Competitors · 5
by search overlapLabcorp21 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
IQVIA19 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Precede15 shared keywordsPrecede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.
Predictive Oncology14 shared keywordsPredictive Oncology combines machine learning with data from a large privately held biobank of over 150,000 tumor samples and 3D in vitro tumor models to predict drug response for pre-clinical drug discovery. It also offers tumor drug-response testing and genomic profiling services to personalize cancer therapies, serving biopharma partners and clinical oncology.
Precision BioSciences12 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Companies competing with Predictabiosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Predictabiosciences do?
- Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.
- Who founded Predictabiosciences?
- Predictabiosciences was founded by Irene Ghobrial, Kenneth Anderson, Gad Getz, Romanos Sklavenitis-Pistofidis, Keith Flaherty in 2023.
- Who are Predictabiosciences's investors?
- Predictabiosciences's investors include Illumina Ventures, The Engine Ventures.
- Where is Predictabiosciences headquartered?
- Predictabiosciences is headquartered in Cambridge, US.